Friday, September 29, 2017
News Recap:
Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...
Pacific AIDS Network (PAN) recently became the fifteenth (15th) organization to sign the HCV Manifesto (http://hepcbc.ca/hcv-manifesto/ . This document, more than simply a list of “rights” transforms the principles developed by persons with HIV/AIDS: GIPA/MIPA (Greater and more Meaningful Involvement of Persons with AIDS in their own care, in the governance of organizations which speak for and support them, and in the broader society as well), and “Nothing
October 23, 2016, Vancouver, BC – HepCBC Hepatitis C Education and Prevention Society (HepCBC) has decided to withdraw from further participation with, and support for, Pacific AIDS Network (PAN).
HepCBC, in an October 13th letter to PAN, stated that PAN – “due to its very nature, history, culture, and organizational structure – [cannot] speak for, nor advocate on behalf of, people with hepatitis C, particularly those in the majority who are mono-infected
